Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Melanotan II | Tesamorelin | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 250-500 mcg daily via subcutaneous injection during loading, reducing to 250 mcg 2-3 times weekly for maintenance. | Research indicates 2 mg administered once daily via subcutaneous injection (FDA-approved dose for HIV lipodystrophy). |
| Timing | Administer 4-6 hours before UV exposure for optimal tanning synergy. Can be taken at any time of day. | Morning administration on empty stomach. Consistent daily timing recommended. |
| Cycle Duration | Loading phase 1-2 weeks, then maintenance as long as desired. Pigmentation fades gradually upon discontinuation. | 26+ weeks in clinical trials. Long-term use is common; effects are not sustained after discontinuation. |
| Evidence Level | moderate_human | Strong (FDA-approved indication), Moderate (longevity) |
Melanotan II is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that non-selectively agonizes melanocortin receptors MC1, MC3, MC4, and MC5. MC1R activation stimulates eumelanin synthesis through tyrosinase upregulation, producing tanning. MC3R activation in the CNS increases libido and produces erectile responses. MC4R activation suppresses appetite. The cyclic structure provides enhanced in vivo stability (half-life 1-2 hours) and increased blood-brain barrier permeability compared to linear alpha-MSH.
Research indicates 250-500 mcg daily via subcutaneous injection during loading, reducing to 250 mcg 2-3 times weekly for maintenance.
Administer 4-6 hours before UV exposure for optimal tanning synergy. Can be taken at any time of day.
Loading phase 1-2 weeks, then maintenance as long as desired. Pigmentation fades gradually upon discontinuation.
Tesamorelin is an FDA-approved synthetic 44-amino acid GHRH analog with a trans-3-hexenoic acid modification at the N-terminal tyrosine that confers resistance to DPP-IV degradation. It binds GHRH receptors on anterior pituitary somatotrophs, stimulating endogenous GH production and secretion while maintaining pulsatile release patterns. Tesamorelin selectively reduces visceral adipose tissue (15-20% reduction in trials) while preserving subcutaneous fat, and markedly increases plasma GH and IGF-1 levels with once-daily dosing.
Research indicates 2 mg administered once daily via subcutaneous injection (FDA-approved dose for HIV lipodystrophy).
Morning administration on empty stomach. Consistent daily timing recommended.
26+ weeks in clinical trials. Long-term use is common; effects are not sustained after discontinuation.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →